Platelet News and Research

RSS

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

BioMimetic Therapeutics, Inc. announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No. 2,583,823 titled "Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof". The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the Company's Augment™ orthopedic product line and certain other rhPDGF-BB product formulations.

17 Dec 2010

Researchers examine outcomes related to antiplatelet therapy in patients undergoing CEA

Despite the common clinical practice among surgeons to discontinue their patients' anti-platelet therapy prior to surgery, a recent study of patients undergoing carotid endarterectomy (CEA) indicated that this practice may be unnecessary.

13 Dec 2010

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

8 Dec 2010

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

BioMimetic Therapeutics, Inc. today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients.

8 Dec 2010

Fluxion Biosciences announces launch of new BioFlux 1000Z system for live cell imaging

Fluxion Biosciences, Inc. announced that the new BioFlux 1000Z system for live cell imaging will be launched at the 50th American Society for Cell Biology Annual Meeting to be held December 11-15, 2010 in Philadelphia, PA. The BioFlux 1000Z is the latest addition to the BioFlux product family of instruments for cellular analysis under controlled shear flow.

From Fluxion Biosciences 7 Dec 2010

Cytomedix receives ISO 13485 and Canadian Medical Device Certification for Gaithersburg facility

Cytomedix, Inc. today announced that it has received certification for the ISO 13485 Quality Management Standard for Medical Devices as well as Canadian Medical Device Certification for its Gaithersburg facility. The announcement certifies Cytomedix as a provider of high-quality devices for the medical industry and allows the Company to operate commercially in Europe and in Canada.

7 Dec 2010

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Two janus kinase (JAK) inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology (ASH) Dec. 4 in Orlando.

7 Dec 2010

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

YM BioSciences Inc. today announced positive interim data from the first 60 patients enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. The results were reported today in an oral presentation at the 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida.

7 Dec 2010

New drug appears to help patients with chronic myeloid leukemia

A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.

7 Dec 2010

$Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH$

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

6 Dec 2010

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

SAGE launches two new journals in Drug Safety, Hematology

SAGE Expands Therapeutic Advances series by launching two new journals in Drug Safety and Hematology. SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.

3 Dec 2010

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen today announced that it will present data from several key Nplate (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.

2 Dec 2010

ASH to host annual meeting for blood disorders at Orange Convention Center

The American Society of Hematology (ASH) will host its 52nd annual meeting at the Orange County Convention Center in Orlando, FL, December 4-7. More than 20,000 attendees are expected for this event, which will highlight emerging research trends in the diagnosis, treatment, and understanding of blood disorders.

1 Dec 2010

Study: Mature blood cells communicate with parent stem cells

A new study by researchers at the Walter and Eliza Hall Institute in Melbourne, Australia, has shown that mature blood cells can communicate with, and influence the behaviour of, their stem cell 'parents'.

30 Nov 2010

DSM wins Most Innovative Health Ingredient Award

DSM Nutritional Products triumphed at this year's HiE Excellence Awards with Fruitflow® - the first natural, scientifically substantiated solution for the promotion of healthy blood flow. As well as winning the Most Innovative Health Ingredient Award, DSM also won an Excellence Award in the category of Heart Health.

25 Nov 2010

Discovery may lead to new generation of drugs to minimize heart attack risk

An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.

24 Nov 2010

New method to generate custom-made platelets from skin cells

Skin cells from humans can be revamped into pro-clotting cells called platelets, according to a study published on November 22 in the Journal of Experimental Medicine.

23 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Platelet News and Research

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

Researchers examine outcomes related to antiplatelet therapy in patients undergoing CEA

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

Fluxion Biosciences announces launch of new BioFlux 1000Z system for live cell imaging

Cytomedix receives ISO 13485 and Canadian Medical Device Certification for Gaithersburg facility

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Amgen announces final study results of Nplate in adults with chronic ITP

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

SAGE launches two new journals in Drug Safety, Hematology

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

ASH to host annual meeting for blood disorders at Orange Convention Center

Study: Mature blood cells communicate with parent stem cells

DSM wins Most Innovative Health Ingredient Award

Discovery may lead to new generation of drugs to minimize heart attack risk

New method to generate custom-made platelets from skin cells

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News